Breaking News
January 17, 2018 - Top nutrients needed to boost mood and energy levels on Blue Monday
January 17, 2018 - Scientists develop unique technique to map elasticity of cell components
January 17, 2018 - Obesity surgery reduces the risk of death by half finds new study
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - In Wisconsin, hopes rise for production of a lifesaving radioactive isotope
January 16, 2018 - Researchers develop software to better predict risk of leakage around aortic stents
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
Esketamine Nasal Spray Eases Depression Quickly

Esketamine Nasal Spray Eases Depression Quickly

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial demonstrated that an intranasal formulation of the s-enantiomer of ketamine had strong anti-depressant effects compared to placebo.
  • Be aware that individuals with psychotic symptoms or a history of psychosis were excluded as the drug could potentiate these symptoms.

An intranasal formulation of ketamine quickly diminished depressive symptoms in patients with treatment-resistant depression, researchers found.

In a phase II study, those taking one of three doses of esketamine (28 mg, 56 mg, or 84 mg) had significantly greater improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores compared with placebo over 8 days, Ella Daly, MD, of Janssen, and colleagues reported online in JAMA Psychiatry.

Those improvements persisted despite reduced dosing frequency in a subsequent open-label phase that lasted about two months, the researchers said.

Several studies have shown ketamine to have antidepressant effects, and there’s been growing interest in this and other NMDA receptor antagonists, in the class of glutamate receptor modulators, to treat depression and suicidality — especially since about a third of patients don’t respond to current treatment options.

A limitation of ketamine, however, is that it needs to be delivered intravenously. So researchers at Janssen developed an intranasal formulation called esketamine, which is the S-enantiomer of ketamine. This version has a higher affinity for the NMDA receptor than the ketamine R-enantiomer, the researchers explained, adding that nasal delivery will also boost bioavailability of the compound. (The chirally pure molecule can also be patented separately from the racemic form.)

The current study enrolled patients at multiple outpatient referral centers from January 2014 to September 2015. It involved four phases: screening; double-blind treatment (days 1-15) composed of two one-week periods; optional open-label treatment (days 15-74); and post-treatment follow-up (8 weeks).

This design allowed for a smaller sample size to assess efficacy, dose-response, and safety than a standard parallel-group design, while preserving a low chance of type 2 error to avoid missing the efficacy signal, the researchers said.

A total of 67 patients (mean age 45) were randomized, and 60 completed both double-blind periods. All had treatment-resistant depression, which was defined as a lack of clinically meaningful improvement after treatment with at least two different oral antidepressants taken at adequate doses. All of them continued to take their oral antidepressants during the study, and esketamine nasal spray was delivered under the supervision of a healthcare professional.

In the first period, participants were randomized to placebo or to one of the three doses of esketamine. In the second phase, 28 placebo-treated patients with moderate-to-severe symptoms were re-randomized to one of the four treatment arms, while those with mild symptoms continued to receive placebo. Finally, during the open-label phase, dosing frequency was reduced from twice weekly to weekly, then to every two weeks.

The primary efficacy endpoint was change from baseline to 8 days on the MADRS scale.

Overall, Daly and colleagues found that the anti-depressant effect was rapid in onset, evident as early as two hours post-dose, and was dose-related. Mean MADRS scores fell in all groups, with significantly greater improvement in all esketamine dose groups compared with placebo, as well as a dose-response relationship.

  • 28 mg: −4.2, P=0.02
  • 56 mg: −6.3, P=0.001
  • 84 mg: −9.0, P<0.001

These improvements persisted over 8 weeks of follow-up without additional esketamine doses in those who remained in the study, the researchers added. Responses “appeared to persist for more than two months with a lower dosing frequency,” they wrote.

During the double-blind phase, the most common treatment-emergent adverse events in esketamine-treated patients were dizziness, headache, and dissociative symptoms. (The latter has been a problem with racemic ketamine; the quasi-hallucinatory effect has made it a drug of abuse, with street names such as Special K.)

Three of 56 esketamine-treated patients discontinued the study during the blinded phase, as did one of 57 patients during the open-label phase. These included one event each of syncope, headache, dissociative syndrome, and ectopic pregnancy. None of the placebo-treated patients discontinued.

Most esketamine-treated patients had transient elevations in blood pressure and heart rate on dosing days, which returned to normal within two hours of the dose. Perceptual changes or dissociative symptoms began shortly after the start of intranasal dosing, peaked at 30 to 40 minutes, and similarly resolved by two hours. These effects attenuated in all dose groups with repeated dosing, and there was no psychosis.

Daly and colleagues concluded that the results support further investigation in larger trials, and the drug is currently being evaluated in phase III trials in treatment-resistant depression and for patients with major depressive disorder who are at immediate risk for suicide.

In an accompanying editorial, Ole Andreassen, MD, PhD, of Oslo University, and colleagues said the significant effects at just one week are “substantially faster than current treatments.”

While esketamine is a good candidate for intranasal delivery, they wrote, some potential barriers include mucosal inflammation, nasal polyps, and septal deviation. Poor self-administration practices can also reduce efficacy, they noted.

Although there was no psychosis in the trial, patients with psychotic disorders or major depressive disorder with psychosis were excluded, Andreassen and colleagues cautioned. They also urged that “the potential for addiction” be evaluated in future studies.

Still, they said the results demonstrate “considerable promise of combining a compound with rapid antidepressant effects with intranasal delivery” and await results from phase III results.

Several authors are employees of Janssen, which funded the study.

The editorialists disclosed financial relationships with Lundbeck and being co-inventors on an intranasal oxytocin delivery device.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-28T16:30:00-0500

Tagged with:

About author

Related Articles